- Home
- MNPR vs TEI Comparison
MNPR vs TEI Comparison
Compare MNPR & TEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- TEI
- Stock Information
- Founded
- MNPR 2014
- TEI 1993
- Country
- MNPR United States
- TEI United States
- Employees
- MNPR N/A
- TEI N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- TEI Finance Companies
- Sector
- MNPR Health Care
- TEI Finance
- Exchange
- MNPR Nasdaq
- TEI Nasdaq
- Market Cap
- MNPR 249.5M
- TEI 256.9M
- IPO Year
- MNPR 2019
- TEI N/A
- Fundamental
- Price
- MNPR $31.73
- TEI $5.64
- Analyst Decision
- MNPR Strong Buy
- TEI
- Analyst Count
- MNPR 5
- TEI 0
- Target Price
- MNPR $59.50
- TEI N/A
- AVG Volume (30 Days)
- MNPR 18.2K
- TEI 142.4K
- Earning Date
- MNPR 05-13-2025
- TEI 01-01-0001
- Dividend Yield
- MNPR N/A
- TEI 10.51%
- EPS Growth
- MNPR N/A
- TEI N/A
- EPS
- MNPR N/A
- TEI N/A
- Revenue
- MNPR N/A
- TEI N/A
- Revenue This Year
- MNPR N/A
- TEI N/A
- Revenue Next Year
- MNPR N/A
- TEI N/A
- P/E Ratio
- MNPR N/A
- TEI N/A
- Revenue Growth
- MNPR N/A
- TEI N/A
- 52 Week Low
- MNPR $1.72
- TEI $4.35
- 52 Week High
- MNPR $54.30
- TEI $5.39
- Technical
- Relative Strength Index (RSI)
- MNPR 37.28
- TEI 65.36
- Support Level
- MNPR $34.02
- TEI $5.48
- Resistance Level
- MNPR $36.82
- TEI $5.66
- Average True Range (ATR)
- MNPR 3.54
- TEI 0.07
- MACD
- MNPR -0.71
- TEI 0.01
- Stochastic Oscillator
- MNPR 27.91
- TEI 92.59
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.